Actualités
Séminaires

Vendredi 15 Avril 2022 de 11h00 à 12h00
SÉMINAIRE IRCM


Lisa Brunet

INSERM U1239 (NorDic) IRIB, Université de Rouen-Normandie, Rouen

 "A new therapeutic strategy to prolong lung cancer response to EGFR inhibitors"

Contact: antonio.maraver@inserm.fr


Mercredi 30 Mars 2022 de 14h00 à 15h00
SEMINAIRE IRCM


Patrick Jouandin

Dept of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Ms., USA

Regulation of Growth during nutrient limitation

contact: alexandre.djiane@inserm.fr

Séminaire en distanciel, un lien Zoom sera diffusé la semaine précédente 


Vendredi 18 Février 2022 de 11h00 à 12h00
Séminaire IRCM


Marie-Caroline Dieu-Nosjean

Immune Microenvironment and Immunotherapy Lab, UMR1135 Inserm, Hopital Pitié-Salpêtriere, Paris.

"Tertiary lymphoid structures: an anti-tumor school for adaptive immune cells and an antibody factory to fight cancer "

contact: nathalie.bonnefoy@inserm.fr


Jeudi 18 Novembre 2021 de 11h00 à 12h30
Séminaire IRCM


Olivier de Wever 

University of Gent, Experimental Cancer Research Lab, Belgium

“From spheroids to extracellular vesicles: finding unknown unknowns to create minimum information guidelines and advance biological understanding”

Contact: jean-pierre.pouget@inserm.fr

Some more on the speaker:

Since his PhD, he has been working on cancer-associated fibroblasts (CAFs) in colon cancer progression (De Wever et al., FASEBJ 2004, J Pathol 2003, J Cell Science 2004 over 1000 cumulative WOS citations). I He expanded his research into adipose tissue during his post-doc (Lapeire et al., Cancer Res 2014) and the secretory mechanisms of pro-metastatic signals (Hendrix et al., JNCI 2010, Cancer Res 2010). His current lab woks on tumor-environment interactions  including design of model systems (De Jaeghere et al., Biomaterials 2018), response to therapy of CAFs (Tommelein et al., Cancer Res 2018), and exploitation of CAFs as therapy (De Vlieghere et al., Biomaterials 2015) and extracellular vesicles with the Hendrix lab (De Wever and Hendrix EMBOJ 2019). 


Jeudi 04 Novembre 2021 à 14h00
Séminaire IRCM


Hervé Técher

Institut de Génétique Humaine, CNRS/Université de Montpellier

Understanding the link(s) between replication stress and inflammation in cancer biology.

contact: celine.gongora@inserm.fr


mercredi 15 septembre à 15h, séminaire Mabimprove


Andrew Kruse

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School

“VHH antibody fragments as tools to interrogate transmembrane receptor signaling”

"Research in Dr Kruse's lab aims to elucidate the molecular basis of transmembrane signaling through the use of biochemistry, pharmacological studies, and structural biology. He is particularly interested in signaling pathways with connections to human health and disease, including G protein-coupled receptors and other transmembrane receptors. In the long term, he aims to leverage a detailed molecular understanding of these pathways to facilitate the development of new and better therapeutics."


Plus d'informations : https://kruse.hms.harvard.edu/home


Jeudi 09 Septembre 2021 de 11h30 à 13h00
séminaire MabImprove-IRCM


Lloyd Bod

Evergrande Center for Immunologic Diseases, Harvard Medical School 

“Tumor-infiltrating B cells: Friends or Foes?”

contact: nathalie.bonnefoy@inserm.fr


Vendredi 17 Septembre 2021 de 11h00 à 13h00
Séminaire IRCM


Maria Casanova

CNIO, Madrid

Tissue-resident macrophages: helpers of early-stage lung tumor development”

Contact : Antonio Maraver

 

 



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés